Abstract:Background: Pralsetinib, a selective oral inhibitor of rearranged during transfection (RET) fusion proteins and oncogenic RET mutants, has shown significant efficacy in treating RET fusion-positive non-small cell lung cancer and thyroid cancer. However, since pralsetinib was approved in the United States in September 2020, there have been limited reports of post-marketing adverse events (AEs). In this study, we aimed to analyze the AE signals with pralsetinib on the basis of the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to provide instructions in clinical practice. Methods: All AE reports were obtained from the FAERS database from the first quarter (Q3) of 2020 to the second quarter (Q2) of 2024. Various signal quantification techniques were used for analysis, including reporting odds ratios, proportional reporting ratios, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker (MGPS)-based empirical Bayesian geometric mean. Results: Out of 8,341,673 case reports in the FAERS database, 1,064 reports of pralsetinib as the "primary suspected (PS)" AEs were recorded, covering 26 system organ classes and 256 preferred terms. Of the reports, 62.5% were from consumers rather than healthcare professionals. The most common systems were general disorders and administration site conditions (n = 704), investigations (n = 516), and gastrointestinal disorders (n = 405). A total of 95 significant disproportionality preferred terms (PTs) conformed to the four algorithms simultaneously. AEs that ranked the top three at the PT level were hypertension (n = 80), asthenia (n = 79), and anemia (n = 65). Of the 95 PTs with significant disproportionation, unexpected significant AEs such as increased blood calcitonin, increased myocardial necrosis marker, and bacterial cystitis were observed, which were not mentioned in the drug's instructions. The median onset time of pralsetinib-associated AEs was 41 days [interquartile range (IQR) 14–86 days]. The majority of the AEs occurred in 30 days (42.86%). Conclusion: Our pharmacovigilance analysis of real-world data from the FEARS database revealed the safety signals and potential risks of pralsetinib usage. These results can provide valuable evidence for further clinical application of pralsetinib and are important in enhancing clinical medication safety.

A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib

A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib

Novel Insights into Post-Marketing Adverse Events Associated with Lenvatinib: A Comprehensive Analysis Utilizing the FAERS Database

Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib

Early Presence of Antiangiogenesis-Related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Patients with Metastatic Gastric Cancer Treated with Apatinib.

Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events

A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system

Adverse events associated with Atogepant: a faers-based pharmacovigilance analysis

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

Mining and evaluation of adverse event signals for capmatinib based on the FAERS database

A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Baricitinib.

Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study

Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database

A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database

Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis

Cellular and Molecular Mechanisms of MEK1 Inhibitor-Induced Cardiotoxicity